TransMedics Q2 revenue $157.4M (+38% YoY), net income $34.9M; raises FY2025 guidance

TransMedics Group, Inc.

2025-Q2 EPS reported $1.62 revenue$300,907,000

Revenue $157.4M vs $114.3M YoY (+38%); net income $34.9M ($0.92 diluted EPS) vs $12.2M.
Raises full-year 2025 revenue guidance to $585M-$605M from $565M-$585M (35% midpoint growth).
Gross margin 61% consistent YoY; operating expenses $60.0M up from $56.8M on R&D investment.
Cash $400.6M; received conditional IDE approval from FDA for Next-Gen OCS Lung trial.
Launched OCS NOP digital ecosystem NOP ACCESS across major U.S. transplant programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.